CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy

HIV Medicine

Volumn 9, Issue 2, 2008, Pages 118-125

  Steel, A ^a   John, L ^a   Shamji, M H ^b   Henderson, D C ^a,b   Gotch, F M ^a   Gazzard, B G ^a   Kelleher, P ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Antiretroviral therapy; CD38; HIV 1; Immune activation

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE;

ADULT; ANTIGENS, CD38; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONDON; MALE; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 38949200267     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00528.x     Document Type: Article

References (35)

1. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169: 3400-3406.
2. Deeks SG, Kitchen CM, Liu L et al. Immune activation set point during early HIV infection predicts subsequent CD4 T-cell changes independent of viral load. Blood 2004; 104: 942-947.
3. Hazenberg MD, Stuart JW, Otto SA et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-255.
4. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, Paul WE. CD4 T-cell depletion in HIV infection: Are we closer to understanding the cause? Nat Med 2002; 8: 319-323.
5. Doisne JM, Urrutia A, Lacabaratz-Porret C et al. CD8 T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004; 173: 2410-2418.
6. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: How CD4 T cells go out of stock. Nat Immunol 2000; 1: 285-289.
7. Ondoa P, Koblavi-Deme S, Borget MY, Nolan ML, Nkengasong JN, Kestens L. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Cote d'Ivoire. Clin Exp Immunol 2005; 140: 138-148.
8. Ondoa P, Dieye TN, Vereecken C et al. Evaluation of HIV-1 p24 antigenemia and level of CD8 CD38 T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal. J Acquir Immune Defic Syndr 2006; 41: 416-424.
9. Onlamoon N, Tabprasit S, Suwanagool S, Louisirirotchanakul S, Ansari AA, Pattanapanyasat K. Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand. Virology 2005; 341: 238-247.
10. Beran O, Holub M, Spala J, Kalanin J, Stankova M. CD38 expression on CD8 T cells in Human immunodeficiency virus 1-positive adults treated with HAART. Acta Virol 2003; 47: 121-124.
11. Bofill M, Mocroft A, Lipman M et al. Increased numbers of primed activated CD8 CD38 CD45RO T cells predict the decline of CD4 T cells in HIV-1-infected patients. AIDS 1996; 10: 827-834.
12. Hazenberg MD, Otto SA, van Benthem BH et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17: 1881-1888.
13. David D, Keller H, Nait-Ighil L et al. Involvement of Bcl-2 and IL-2R in HIV-positive patients whose CD4 cell counts fail to increase rapidly with highly active antiretroviral therapy. AIDS 2002; 16: 1093-1101.
14. Hunt PW, Martin JN, Sinclair E et al. T cell activation is associated with lower CD4 T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
15. Nkengasong JN, Kestens L, Ghys PD et al. Human immunodeficiency virus Type 1 (HIV-1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Cote d'Ivoire. J Infect Dis 2001; 183: 1405-1408.
16. Aziz N, Nishanian P, Taylor JM et al. Stability of plasma levels of cytokines and soluble activation markers in patients with human immunodeficiency virus infection. J Infect Dis 1999; 179: 843-848.
17. Mocroft A, Bofill M, Lipman M et al. CD8, CD38 lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 158-162.
18. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8 T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4 cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 83-92.
19. Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV. CD8 T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 332-340.
20. Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
21. Karlsson AC, Younger SR, Martin JN et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18: 981-989.
22. Benito JM, Lopez M, Lozano S et al. CD4 T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8 T cell activation. J Infect Dis 2005; 192: 2142-2146.
23. Benito JM, Lopez M, Lozano S, Martinez P, Gonzalez-Lahoz J, Soriano V. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20: 227-233.
24. Tilling R, Kinloch S, Goh LE et al. Parallel decline of CD8/CD38 T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS 2002; 16: 589-596.
25. Wellons MF, Ottinger JS, Weinhold KJ et al. Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. J Infect Dis 2001; 183: 1522-1525.
26. Steinbrook R. HIV in India - the challenges ahead. N Engl J Med 2007; 356: 1197-1201.
27. Lenkei R, Bratt G, Holmberg V, Muirhead K, Sandstrom E. Indicators of T-cell activation: Correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV-positive individuals and healthy controls. Cytometry 1998; 33: 115-122.
28. Perfetto SP, Malone JD, Hawkes C et al. CD38 expression on cryopreserved CD8 T cells predicts HIV disease progression. Cytometry 1998; 33: 133-137.
29. Kalayjian RC, Landay A, Pollard RB et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: Association of age and HIV infection with naïve CD8 cell depletion, reduced expression of CD28 on CD8 cells, and reduced thymic volumes. J Infect Dis 2003; 187: 1924-1933.
30. Clerici M, Butto S, Lukwiya M et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 2000; 14: 2083-2092.
31. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 2002-2011.
32. Lugada ES, Mermin J, Kaharuza F et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol 2004; 11: 29-34.
33. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults - a monocentric German study. Clin Immunol 2005; 116: 192-197.
34. Koesters SA, Matu L, Kiama P et al. Elevation of immune activation in Kenyan women is associated with alterations in immune function: implications for vaccine development. J Clin Immunol 2004; 24: 702-709.
35. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.